Leap Therapeutics Stock Surges 25% on $59M Winklevoss Capital Crypto Investment Deal

Leap Therapeutics (LPTX) shares skyrocketed 25% following the announcement of a $58.9 million private investment led by Winklevoss Capital, marking a significant move into cryptocurrency treasury strategy. The investment package includes common shares and warrants priced at $0.61439 per unit, with Winklevoss Capital securing two board seats at the immuno-oncology company. While specific cryptocurrency allocations remain undisclosed, Leap confirmed it will allocate a portion of the capital to purchase digital assets for long-term balance sheet holdings, joining other public companies adopting crypto treasury reserves. The remaining funds will advance clinical development of Leap's drug pipeline, with further digital asset strategy details expected soon.